AstraZeneca, the Anglo-Swedish pharmaceuticals group, is to pay $15.6bn in cash to acquire MedImmune, the US biotechnology business, in a fresh consolidation of the drugs sector.

The deal, which follows a competitive auction, marks the latest bid by AstraZeneca to strengthen its pipeline of experimental drugs, expanding biological products and extending into vaccines for the first time.